Nitrolingual is owned by Pohl Boskamp.
Nitrolingual contains Nitroglycerin.
Nitrolingual has a total of 1 drug patent out of which 0 drug patents have expired.
Nitrolingual was authorised for market use on 31 October, 1985.
Nitrolingual is available in spray, metered;sublingual dosage forms.
Nitrolingual can be used as method of treating angina pectoris.
The generics of Nitrolingual are possible to be released after 12 March, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7872049||POHL BOSKAMP||Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate|| |
(6 years from now)
Market Authorisation Date: 31 October, 1985
Treatment: Method of treating angina pectoris
Dosage: SPRAY, METERED;SUBLINGUAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic